As of November 6, 2026, Champions Oncology, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 30, 2026 (Form 8-K, March 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Champions Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Champions Oncology, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-30. Every row below is cited to the filing it comes from, and this page adds each new change as Champions Oncology, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-30 | Reported | not named in the filing | 8-K, 2026-03-30 |
Selling to them or working with them? See who runs Champions Oncology, Inc. now and the warning signs.
Free to see. No signup.
Watch Champions Oncology, Inc.
Get an email when Champions Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Champions Oncology, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Champions Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Champions Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on Champions Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Champions Oncology, Inc., with the record behind each one.
Find candidates like senior executive at Champions Oncology, Inc.Every change, in the filing's words
Reported
On March 24, 2026, the Board of Directors (the "Board") of Champions Oncology, Inc. (the "Company") accepted the resignation of Dr. Philip Breitfeld as a member of the Board and appointed Dr. Brian Alexander as a director of the Company to fill the vacancy created by Dr. Breitfeld's resignation.
- Dr. Breitfeld's decision to resign was not due to any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The following is certain biographical information regarding Dr. Alexander: Dr. Alexander, MD, MPH, serves as the Chief Executive Officer of Valo Health Inc., a company dedicated to utilizing artificial intelligence (AI) and advanced analytics to learn from patient experiences and accelerate the discovery and development of superior medicines at increased speed and scale, since November 2024.
- Additionally, he holds the position of CEO-Partner at Flagship Pioneering since November 2024.
- Prior to joining Valo Health and Flagship Pioneering, Dr. Alexander worked as the Senior Vice President for Research & Development at Roche/Genentech, from November 2023 to November 2024, working to leverage data sciences and AI/ML approaches for innovative clinical developmental strategies.
- From 2018 to November 2023, Dr. Alexander held various positions at Foundation Medicine, including the role of Chief Executive Officer beginning in April 2021.
Tools for this story
Each opens in a new tab, filled in for Champions Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.